Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Receivables - Accured (2023 - 2025)

Kura Oncology (KURA) has disclosed Receivables - Accured for 3 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • Quarterly Receivables - Accured rose 15.15% to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, up 15.15% year-over-year, with the annual reading at $3.8 million for FY2025, 15.15% up from the prior year.
  • Receivables - Accured for Q4 2025 was $3.8 million at Kura Oncology, up from $3.3 million in the prior quarter.
  • The five-year high for Receivables - Accured was $3.9 million in Q1 2025, with the low at $900000.0 in Q1 2023.
  • Average Receivables - Accured over 3 years is $2.3 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Receivables - Accured surged 200.0% in 2024, then grew 15.15% in 2025.
  • Over 3 years, Receivables - Accured stood at $1.1 million in 2023, then soared by 200.0% to $3.3 million in 2024, then increased by 15.15% to $3.8 million in 2025.
  • According to Business Quant data, Receivables - Accured over the past three periods came in at $3.8 million, $3.3 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.